Brain natriuretic peptide-guided therapy for heart failure

References

• Miller R R, Vismara L A, Williams D O, Amsterdam E A, Mason D T. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circ Res 1976; 39: 127–33
   PubMed Web of Science ®Google Scholar
• Cohn J N, Franciosa J A. Drug therapy. Vasodilator therapy of cardiac failure. N Engl J Med 1977; 297: 27–31
   PubMed Web of Science ®Google Scholar
• Colucci W S, Wynne J, Holman B L, Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol 1980; 45: 337–44
   PubMed Web of Science ®Google Scholar
• Packer M, Meller J, Medina N, Yushak M, Gorlin R. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. N Engl J Med 1982; 306: 57–62
   PubMed Web of Science ®Google Scholar
• Packer M. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol 1983; 2: 841–52
   PubMed Web of Science ®Google Scholar
• Cohn J N, Archibald D G, Ziesche S, Franciosa J A, Harston W E, Tristani F E, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–52
   PubMed Web of Science ®Google Scholar
• Packer M, Medina N, Yushak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. J Am Coll Cardiol 1986; 7: 671–80
   PubMed Web of Science ®Google Scholar
• Cohn J N, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med 1987; 316: 1429–35
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91
   PubMed Web of Science ®Google Scholar
• Bristow M R, Gilbert E M, Abraham W T, Adam K F, Fowler M B, Hershberger R E, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–16
   PubMed Web of Science ®Google Scholar
• Colucci W S, Packer M, Bristow M R, Gilbert M, Cohn J N, Fowler M B, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800–6
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow M R, Cohn J N, Colucci W S, Fowler M B, Gilbert E M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996; 334: 1349–55
   PubMed Web of Science ®Google Scholar
• Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–80
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7
   PubMed Web of Science ®Google Scholar
• Califf R M, O'Connor C M. Beta-blocker therapy for heart failure. The evidence is in, now the work begins. JAMA 2000; 283: 1335–7
   PubMed Web of Science ®Google Scholar
• Whorlow S L, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am J Cardiol 2000; 86: 886–9
   PubMed Web of Science ®Google Scholar
• Packer M, Coats A JS, Fowler M B, Katus H A, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–8
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W J, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999; 241: 709–17
   Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33
   PubMed Web of Science ®Google Scholar
• Willenheimer R, Swedberg K. Dressing heart-failure patients on Savile Row - tailored treatment. Lancet 2000; 355: 2012–13
   PubMed Web of Science ®Google Scholar
• Stevenson L W, Tillisch J H, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1348–54
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Fyhrquist F, Metsärinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985; 2: 66–9
   PubMed Web of Science ®Google Scholar
• Burnett J C, Kao P C, Hu D C, Heser D W, Heublein D, Granger J P, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145–7
   PubMed Web of Science ®Google Scholar
• Richards A M, Cleland J GF, Tonolo G, McIntyre G D, Leckie B J, Dargie H J, et al. Plasma alpha natriuretic peptide in cardiac impairment. BMJ 1986; 293: 409–12
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Hosoda K, Suga S -I, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991; 87: 1402–12
   PubMed Web of Science ®Google Scholar
• Hunt P J, Richards A M, Nicholls M G, Yandle T G, Doughty R N, Espiner E A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287–96
   PubMed Web of Science ®Google Scholar
• Anderson J V, Gibbs J SR, Woodruff P WR, Greco C, Rowland E, Bloom S R. The plasma atrial natriuretic peptide response to treatment of acute cardiac failure, spontaneous supra-ventricular tachycardia and induced re-entrant tachycardia in man. J Hypertens 1986; 4(Suppl 2)S137–41
   Google Scholar
• Crozier I G, Nicholls M G, Ikram H, Espiner E A, Yandle T G. Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exper Pharmacol Physiol 1989; 16: 417–24
   PubMed Web of Science ®Google Scholar
• Webster M WI, Sharpe N, Coxon R, Murphy J, Hannan S, Nicholls M G, et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 1989; 63: 217–21
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Yasue H, Tanaka H, Kikuta K, Sumida H, Kato H, et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 1994; 72: 528–33
   PubMedGoogle Scholar
• Murdoch D R, McDonagh T A, Byrne J, Blue L, Farmer R, Morton J J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart 1999; 138: 1126–32
   PubMed Web of Science ®Google Scholar
• Sanderson J E, Chan W WM, Hung Y T, Chan S KW, Shum I OL, Raymond K, et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995; 74: 502–7
   PubMedGoogle Scholar
• Hara Y, Hamada M, Shigematsu Y, Suzuki M, Kodama K, Kuwahara T, et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000; 64: 365–9
   PubMedGoogle Scholar
• Doughty R N, Whalley G A, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am Coll Cardiol 1997; 29: 1060–6
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, Hisanaga T, Fukai D, Maeda Y, et al. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 1997; 134: 910–6
   PubMed Web of Science ®Google Scholar
• Troughton R W, Frampton C M, Yandle T G, Espiner E A, Nicholls M G, Richards A M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–30
   PubMed Web of Science ®Google Scholar
• Lainchbury J G, Espiner E A, Frampton C M, Richards A M, Yandle T G, Nicholls M G. Cardiac natriuretic peptides as predictors of mortality. J Int Med 1997; 241: 257–9
   PubMed Web of Science ®Google Scholar
• Richards A M, Nicholls M G, Yandle T G, Frampton C, Espiner E A, Turner J G, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921–9
   PubMed Web of Science ®Google Scholar
• Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for de-compensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386–91
   PubMed Web of Science ®Google Scholar
• Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379–85
   PubMed Web of Science ®Google Scholar